Company Overview

4D Molecular Therapeutics, Inc. (“4DMT”) is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for serious diseases with high unmet medical need. The company operates within the biotechnology and genetic medicine industries, with a primary emphasis on ophthalmology, pulmonology, and cardiology. Its core business model centers on discovering and developing proprietary AAV vectors designed to improve tissue targeting, durability, and therapeutic delivery compared with conventional gene therapy platforms. Revenue generation has historically been limited and primarily associated with collaboration agreements and financing activities, as the company remains in the clinical development stage rather than commercial operations.

The company’s strategic positioning is closely tied to its proprietary Therapeutic Vector Evolution platform, which is designed to create customized AAV capsids with enhanced specificity and reduced immunogenicity. 4DMT was founded in 2013 and later became publicly traded on Nasdaq under the ticker FDMT. Since inception, the company has expanded from platform development into a pipeline of clinical and preclinical gene therapy candidates, particularly targeting inherited retinal diseases and pulmonary conditions. Public disclosures in SEC filings and investor presentations indicate that the company seeks to differentiate itself through targeted vector engineering and potentially lower dosing requirements relative to competing AAV-based therapies.

Business Operations

4DMT organizes its operations primarily around gene therapy research, clinical development, and vector discovery technologies. Its development pipeline includes programs such as 4D-150 for wet age-related macular degeneration and diabetic macular edema, as well as pulmonary-focused candidates including 4D-710 for cystic fibrosis lung disease. The company’s proprietary Therapeutic Vector Evolution platform represents a core operational asset, enabling the discovery and optimization of novel AAV vectors intended for specific tissues and disease applications. Operations are largely research-driven, with spending concentrated on clinical trials, manufacturing development, regulatory activities, and platform innovation.

The company’s activities are centered primarily in the United States, though clinical trial activities and collaborations may extend internationally through contract research organizations and manufacturing partners. 4DMT has engaged in strategic partnerships over time, including prior collaborations with large pharmaceutical companies and academic institutions to support development and translational research. The company also relies on third-party manufacturers and specialized contract development organizations for portions of its production and clinical supply chain. Publicly available filings identify intellectual property, proprietary capsid libraries, and clinical-stage gene therapy candidates as key operational assets.

Strategic Position & Investments

4DMT’s strategic direction is focused on advancing late-stage ophthalmology programs while expanding the applicability of its vector platform into additional therapeutic areas. The company has invested heavily in clinical development for retinal diseases, particularly through the advancement of 4D-150, which has been positioned as a potentially durable intravitreal gene therapy candidate. Management has also emphasized pulmonary gene therapy as a long-term growth opportunity, particularly through the development of 4D-710 for cystic fibrosis patients who are not adequately treated by existing modulator therapies.

In addition to internal pipeline investment, the company has allocated resources toward manufacturing capabilities, vector optimization technologies, and intellectual property expansion. Public disclosures indicate continued investment in next-generation AAV engineering and translational research intended to improve delivery efficiency and durability. 4DMT’s strategy reflects broader industry movement toward precision-targeted genetic medicines, though the company remains dependent on successful clinical outcomes, regulatory approvals, and access to capital markets to support ongoing development.

Geographic Footprint

4DMT is headquartered in Emeryville, California, and its primary operational footprint is concentrated within the United States. Research, corporate management, and core development activities are largely conducted domestically, particularly within biotechnology hubs in California. The company’s clinical and regulatory activities are primarily aligned with the U.S. biotechnology and healthcare ecosystem, including interactions with the U.S. Food and Drug Administration.

Despite its domestic base, 4DMT maintains an international presence through global clinical development infrastructure, manufacturing relationships, and scientific collaborations. Clinical trial participation and operational support may involve sites and vendors across North America and selected international regions. The company’s technologies are relevant to global therapeutic markets, particularly in ophthalmology and rare disease treatment areas where multinational commercialization opportunities could emerge if products receive regulatory approval.

Leadership & Governance

4DMT was founded by scientists and biotechnology executives focused on advancing engineered AAV gene therapy technologies. The company is led by executives with backgrounds spanning genetic medicine, biotechnology commercialization, clinical development, and pharmaceutical operations. Public company governance is overseen by a board of directors and executive leadership team responsible for pipeline execution, capital allocation, regulatory strategy, and long-term platform development.

The leadership team has consistently emphasized scientific innovation, disciplined clinical execution, and development of differentiated vector technologies as central pillars of corporate strategy. According to company filings and investor communications, management’s strategic vision centers on creating durable gene therapies capable of addressing diseases that remain underserved by current standards of care.

• David Kirn, M.D. – Chief Executive Officer and Co-Founder
• Andrew Gold, M.D. – Chief Medical Officer
• Pankaj Doshi – Chief Business Officer
• Jiong Lan, Ph.D. – Chief Technical Officer
• Katherine A. High, M.D. – Independent Director
• Lynn Seely, M.D. – Chair of the Board of Directors